Abstract
Prostaglandin D2(PGD2) causes cough and levels are increased in asthma suggesting that it may contribute to symptoms. Although the prostaglandin D2receptor 2 (DP2) is a target for numerous drug discovery programmes little is known about the actions of PGD2on sensory nerves and cough.We used human and guinea pig bioassays,in vivoelectrophysiology and a guinea pig conscious cough model to assess the effect of prostaglandin D2receptor (DP1), DP2and thromboxane receptor antagonism on PGD2responses.PGD2caused cough in a conscious guinea pig model and an increase in calcium in airway jugular ganglia. Using pharmacology and receptor-deficient mice we showed that the DP1receptor mediates sensory nerve activation in mouse, guinea pig and human vagal afferents.In vivo, PGD2and a DP1receptor agonist, but not a DP2receptor agonist, activated single airway C-fibres. Interestingly, activation of DP2inhibited sensory nerve firing to capsaicinin vitroandin vivo.The DP1receptor could be a therapeutic target for symptoms associated with asthma. Where endogenous PGD2levels are elevated, loss of DP2receptor-mediated inhibition of sensory nerves may lead to an increase in vagally associated symptoms and the potential for such adverse effects should be investigated in clinical studies with DP2antagonists.

This publication has 47 references indexed in Scilit: